Bibn 99 | CAS#145301-48-0 | M2 antagonist

MedKoo Cat#: 584199 | Name: Bibn 99

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bibn 99 is a lipophilic and selective muscarinic M2 receptor antagonist with applications to cognitive performance and Alzheimer's Disease.

Chemical Structure

Bibn 99

CAS#145301-48-0

Theoretical Analysis

MedKoo Cat#: 584199

Name: Bibn 99

CAS#: 145301-48-0

Chemical Formula: C31H42ClN5O3

Exact Mass: 567.2976

Molecular Weight: 568.16

Elemental Analysis: C, 65.53; H, 7.45; Cl, 6.24; N, 12.33; O, 8.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Bibn-99; Bibn 99; Bibn99

IUPAC/Chemical Name

Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-

InChi Key

LUPAFPUKESJDMZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C31H42ClN5O3/c1-5-15-31(3,4)30(40)36(6-2)17-8-9-22-13-18-35(19-14-22)21-27(38)37-26-12-11-23(32)20-24(26)29(39)34-25-10-7-16-33-28(25)37/h7,10-12,16,20,22H,5-6,8-9,13-15,17-19,21H2,1-4H3,(H,34,39)

SMILES Code

CCCC(C)(C)C(N(CCCC1CCN(CC(N2C3=NC=CC=C3NC(C4=CC(Cl)=CC=C42)=O)=O)CC1)CC)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 568.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Doods HN, Quirion R, Mihm G, Engel W, Rudolf K, Entzeroth M, Schiavi GB, Ladinsky H, Bechtel WD, Ensinger HA, et al. Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology. Life Sci. 1993;52(5-6):497-503. Review. PubMed PMID: 8441330. 2: Rowe WB, O'Donnell JP, Pearson D, Rose GM, Meaney MJ, Quirion R. Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats. Behav Brain Res. 2003 Oct 17;145(1-2):171-8. PubMed PMID: 14529815. 3: Quirion R, Wilson A, Rowe W, Aubert I, Richard J, Doods H, Parent A, White N, Meaney MJ. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. J Neurosci. 1995 Feb;15(2):1455-62. PubMed PMID: 7869110. 4: Tombaugh GC, Rowe WB, Chow AR, Michael TH, Rose GM. Theta-frequency synaptic potentiation in CA1 in vitro distinguishes cognitively impaired from unimpaired aged Fischer 344 rats. J Neurosci. 2002 Nov 15;22(22):9932-40. PubMed PMID: 12427850. 5: Daniel JM, Dohanich GP. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. J Neurosci. 2001 Sep 1;21(17):6949-56. PubMed PMID: 11517282. 6: Müller DM, Mendla K, Farber SA, Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci. 1997;60(13-14):985-91. PubMed PMID: 9121365. 7: Pike BR, Hamm RJ. Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats. Brain Res. 1995 Jul 17;686(1):37-43. PubMed PMID: 7583269. 8: Greenlee W, Clader J, Asberom T, McCombie S, Ford J, Guzik H, Kozlowski J, Li S, Liu C, Lowe D, Vice S, Zhao H, Zhou G, Billard W, Binch H, Crosby R, Duffy R, Lachowicz J, Coffin V, Watkins R, Ruperto V, Strader C, Taylor L, Cox K. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Farmaco. 2001 Apr;56(4):247-50. Review. PubMed PMID: 11421251. 9: Watanabe T, Kakefuda A, Tanaka A, Takizawa K, Hirano S, Shibata H, Yamagiwa Y, Yanagisawa I. Synthesis and biological evaluation of phenylacetyl derivatives having low central nervous system permeability as potent and selective M2 muscarinic receptor antagonists. Chem Pharm Bull (Tokyo). 1998 Jan;46(1):53-68. PubMed PMID: 9468637. 10: Doods H, Entzeroth M, Ziegler H, Schiavi G, Engel W, Mihm G, Rudolf K, Eberlein W. Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur J Pharmacol. 1993 Sep 21;242(1):23-30. PubMed PMID: 8223934. 11: Nikolov R. Alzheimer's disease therapy - an update. Drug News Perspect. 1998 May;11(4):248-55. PubMed PMID: 15616667. 12: Kelley BM, Porter JH. The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav. 1997 Aug;57(4):707-19. PubMed PMID: 9258998. 13: Nobuhara K, Halldin C, Hall H, Karlsson P, Farde L, Hiltunen J, McPherson DW, Savonen A, Bergström KA, Pauli S, Swahn CG, Larsson SA, Schnell PO, Sedvall G. Z-IQNP: a potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer's disease. Psychopharmacology (Berl). 2000 Mar;149(1):45-55. PubMed PMID: 10789882. 14: Ikonen S, Tanila H. Effects of metrifonate on the hippocampal theta rhythm of freely moving intact and MS-lesioned mice. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):165-72. PubMed PMID: 11420082. 15: Kozlowski JA, Lowe DB, Guzik HS, Zhou G, Ruperto VB, Duffy RA, McQuade R, Crosby G, Taylor LA, Billard W, Binch H, Lachowicz JE. Diphenyl sulfoxides as selective antagonists of the muscarinic M2 receptor. Bioorg Med Chem Lett. 2000 Oct 16;10(20):2255-7. PubMed PMID: 11055332. 16: Cohen VI, Jin B, McRee RC, Boulay SF, Cohen EI, Sood VK, Zeeberg BR, Reba RC. In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiazepinones and pyridobenzodiazepinones. Brain Res. 2000 Apr 10;861(2):305-15. PubMed PMID: 10760492.